We are live on ! Find out more
NAGE icon

Niagen Bioscience

58 hedge funds and large institutions have $51.2M invested in Niagen Bioscience in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

319% more capital inflows, than outflows

Capital inflows: $5.92M | Capital outflows: $1.41M

54% more call options, than puts

Call options by funds: $106K | Put options by funds: $69K

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

14% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 14

1.64% more ownership

Funds ownership: 18.21% → 19.86% (+1.6%)

0% more funds holding

Funds holding: 58 → 58 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
58
Holders Change
–
Holders Change %
0%
% of All Funds
1.25%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
16
Reduced
14
Closed
6
Calls
$106​K
Puts
$69​K
Net Calls
+$37​K
Net Calls Change
+$40​K

NAGE Hedge Fund Activity: Q2 2019 in Review

58 of the 4,627 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q2 2019, worth a combined $51.2M — up 21% from $42.2M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new NAGE positions and 6 closed out — a net gain of 2 holders — while 16 added to existing stakes and 14 trimmed.

The largest buyer was Uniplan Investment Counsel, opening a new position worth an estimated $3.01M. The largest seller was Granite Investment Partners, cutting an estimated $334K.

  • 58 institutional investors held Niagen Bioscience (NAGE) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $51.2M of Niagen Bioscience stock for Q2 2019, up 21% quarter-over-quarter.
  • 8 funds opened new Niagen Bioscience positions in Q2 2019 and 6 closed out, a net change of +2 holders.
  • The largest Niagen Bioscience buyer in Q2 2019 was Uniplan Investment Counsel, an estimated $3.01M added.
  • The largest Niagen Bioscience seller in Q2 2019 was Granite Investment Partners, an estimated $334K sold.

Based on aggregated 13F filings for Q2 2019.